A Case of Mucinous Cystadenoma Carcinoma

Abstract

Introduction: Mucinous Cystadenoma carcinoma is a type of tumor in the cyst adenocarcinoma grouping it can occur in the breast as well as the ovary. Tumors are normally multiocular with various smooth thin-walled cysts. Within the cyst is found an emergence or cellular debris. Patient History: The female patient 63-year-old who was admitted to AVBRH on the date 21/05/2021 in the obstetric and gynae ward with a chief complaint of generalized weakness, loss of appetite, fever for 2 days 7 days ago, 2-3 fever spikes and burning micturition. All over investigation observed like blood and urine investigation, CT scan of the abdomen, histopathology then the final diagnosis is confirmed as mucinous Cystadenoma carcinoma. Pharmacology: The patient was treated with antibacterial medicine, antibiotics, and diabetics, thyroxin stimulating drugs, etc. Management: Inj. Ceftriaxone 1gm 12 hourly, Inj.-piptaz 4.45 gm, 8 hourly, tab. Gimipride 0.5 mg with tab. Metformin 500 mg 12 hourly, tab. Thyrox 62.5 mcg, tab Case Study Hatwar et al.; JPRI, 33(52A): 148-152, 2021; Article no.JPRI.75948 149 telmisartan 40 mg with tab. Chlorthalidone 12.512.5 mg 12 hourly, Inj.-pan 40 mg, 12 hourly, Inj.-Neomol 100 ml, and Tablet-nitrofurantoin 6 hourly. Nursing Management: Monitor the vital sign, monitor nutritional status and monitor random blood sugar. Maintained bed rest of patient, managed the pain level of the patient. The patient was assessed for risk of bleeding. Conclusion: The patient was admitted to the hospital with the chief complaint of generalized weakness, loss of appetite, fever for 2 days 7 days ago, 2-3 fever spikes and burning micturition. and the patient was admitted to AVBR Hospital in the obstetric and gynae ward, immediate treatment was started by a health team member and all possible treatments were given and now the patient's condition is satisfactory.

Full text

_____________________________________________________________________________________________________
*Corresponding author: E-mail: vaibhavhat12@gmail.com;
Journal of Pharmaceutical Research International
33(52A): 148-152, 2021; Article no.JPRI.75948
ISSN: 2456-9119
(Past name: British Journal of Pharmaceutical Research, Past ISSN: 2231-2919,
NLM ID: 101631759)
A Case of Mucinous Cystadenoma Carcinoma
Vaibhav G. Hatwar a*, Ranjana Sharma b, Mayur Wanjari c, Pratibha Wankhede c,
Sagar Alwadkar c and Hina Rodge d
a Smt. Radhikabai Meghe Memorial College of Nursing, Datta Meghe Institute of Medical Sciences,
Sawangi (M), Wardha, India.
b Department of Medical Surgical Nursing, Smt. Radhikabai Meghe Memorial College of Nursing,
Datta Meghe Institute of Medical Sciences, Sawangi (M), Wardha, India.
c Department of Community Health Nursing, Smt. Radhikabai Meghe Memorial College of Nursing,
Datta Meghe Institute of Medical Sciences, Sawangi (M), Wardha, India.
d Department of Child Health Nursing, Smt. Radhikabai Meghe Memorial College of Nursing, Datta
Meghe Institute of Medical Sciences, Sawangi (M), Wardha, India.
Authors’ contributions
This work was carried out in collaboration among all authors. All authors read and approved the final
manuscript.
Article Information
DOI: 10.9734/JPRI/2021/v33i52A33568
Editor(s):
(1) Dr. Syed A. A. Rizvi, Nova Southeastern University, USA.
Reviewers:
(1) Riccardo Beltrami, The University of Pavia, Italy.
(2) Lucia Maria Jaeger de Carvalho, Universidade Federal do Rio de Janeiro, Brazil.
Complete Peer review History, details of the editor(s), Reviewers and additional Reviewers are available here:
https://www.sdiarticle5.com/review-history/75948
Received 22 August 2021
Accepted 28 October 2021
Published 27 November 2021
ABSTRACT
Introduction: Mucinous Cystadenoma carcinoma is a type of tumor in the cyst adenocarcinoma
grouping it can occur in the breast as well as the ovary. Tumors are normally multiocular with
various smooth thin-walled cysts. Within the cyst is found an emergence or cellular debris.
Patient History: The female patient 63-year-old who was admitted to AVBRH on the date
21/05/2021 in the obstetric and gynae ward with a chief complaint of generalized weakness, loss of
appetite, fever for 2 days 7 days ago, 2-3 fever spikes and burning micturition. All over investigation
observed like blood and urine investigation, CT scan of the abdomen, histopathology then the final
diagnosis is confirmed as mucinous Cystadenoma carcinoma.
Pharmacology: The patient was treated with antibacterial medicine, antibiotics, and diabetics,
thyroxin stimulating drugs, etc. Management: Inj. Ceftriaxone 1gm 12 hourly, Inj.-piptaz 4.45 gm, 8
hourly, tab. Gimipride 0.5 mg with tab. Metformin 500 mg 12 hourly, tab. Thyrox 62.5 mcg, tab
Case Study

Hatwar et al.; JPRI, 33(52A): 148-152, 2021; Article no.JPRI.75948
149
telmisartan 40 mg with tab. Chlorthalidone 12.512.5 mg 12 hourly, Inj.-pan 40 mg, 12 hourly, Inj.-
Neomol 100 ml, and Tablet- nitrofurantoin 6 hourly.
Nursing Management: Monitor the vital sign, monitor nutritional status and monitor random blood
sugar. Maintained bed rest of patient, managed the pain level of the patient. The patient was
assessed for risk of bleeding.
Conclusion: The patient was admitted to the hospital with the chief complaint of generalized
weakness, loss of appetite, fever for 2 days 7 days ago, 2-3 fever spikes and burning micturition.
and the patient was admitted to AVBR Hospital in the obstetric and gynae ward, immediate
treatment was started by a health team member and all possible treatments were given and now
the patient's condition is satisfactory.
Keywords: Mucinous cystadenoma carcinoma; dj stenting; medical management; pharmacology.
1. INTRODUCTION
Mucinous Cystadenoma carcinoma is a benign
cystic tumor lined by a mucinous epithelium. It is
a type of cystic adenoma (cystadenoma) [1,2].
Mucinous cystadenomata may arise in several
locations however mucinous cystadenoma at
different locations is not generally considered to
be related to one another [3,4].
1.1 Incidence
Benign mucinous cystadenoma composed 80%
of the mucinous ovarian tumor and 20 to 25% of
benign ovarian tumors overall. The peak
incidence occurs between 30 and 50 years of
age [5]. Benign tumors are bilateral in 5 to 10%
of the cases.
1.2 Objective
1. To know general idea regarding disease
condition.
2. To explore knowledge regarding
pharmacology, medical and nursing
management.
2. PATIENT INFORMATION
2.1 Patient Present History
The female patient 63-year-old who was
admitted to AVBRH on the date 21/05/2021 in
the obstetric and gynae ward with a chief
complaint of generalized weakness, loss of
appetite, fever for 2 days 7 days ago, 2-3 fever
spikes and burning micturition. All over
investigation observed like blood and urine
investigation, CT scan of the abdomen,
histopathology then the final diagnosis is
confirmed as mucinous Cystadenoma carcinoma
[6].
2.2 Past History
The patient was not having any history of
communicable disease, asthma, tuberculosis, but
the patient was having diabetes. The patient was
COVID - positive. The patient had undergone a
DJ stenting surgical procedure on the right side
on date 25/05/2021
2.3 Causes
Unknown, Genetic inheritance
2.4 Clinical Finding
1. Emesis
2. Fatigue
3. Indigestion
4. Constipation
5. Urinary incontinence
6. Abdominal or pelvic pain
7. Increasing Abdominal girth
2.5 Diagnosis Evaluation
1. History collection-Done.
2. Physical examination- Done
3. CT scan -Done
4. Others: ECG, CBC, Histopathology
2.6 Blood Investigation Report
Investigation
Patient Value
Normal Value
Justification
Complete Blood
Count
1. HB%
11%
92.4cub.micron
13-15.5%
80-90cub.micron
Decreased
Increased

Hatwar et al.; JPRI, 33(52A): 148-152, 2021; Article no.JPRI.75948
150
Investigation
Patient Value
Normal Value
Justification
2. MCV
3. MCH
4. Total RBC
Count
5. Total WBC
Count
6. Total platelet
count
7. Monocytes
31.2 Pico gm.
3.51million/cu.mm
9600 cu.mm
2.4 lacs/cu.mm
04 %
26.5-33.5 Pico gm.
4.5-6 million/cu.mm
4000-11000 cu.mm
1.5-4 lacs/cu.mm
4-10%
Normal
Decreased
Normal
Normal
Normal
KFT
1. Urea
2. Creatinine
3. Sodium
4. Potassium
15 mg%
0.9 mg%
133 meq/l
4.4 mmeq/l
18-40 mg%
0.7- 1.5 mg%
136-145 meq/l
3.5 – 5.1mmeq/l
Increased
Normal
Decreased
Normal
LFT
1. Total protein
2. Albumin
3. Total bilirubin
7.2 gm.%
3.7 gm.%
0.8 mg%
6-8 gm. %
3-5 gm.%
0.3 – 1 mg%
Normal
Normal
Normal
RTPCR: - POSITIVE
2.6 CT SCAN
Previous pelvic mass lesion presently measures
approximately 5.5 x 6*5.2 shown to decrease in
size as compared to previous with mild extension
into the urinary bladder lumen. Lesion posteriorly
involving adjacent rectosigmoid wall thickening a
significant change in the size of compared to the
previous CECT
3. MEDICAL THERAPY
3.1 Pharmacology Therapy
1. Antibacterial medicine
2. Antibiotics
3. Antidiabetics
4. Thyroxin stimulating drug
3.2 Medical Management
Now patient treatment in the ward is Inj.
Ceftriaxone 1gm 12hourly, Inj.-piptaz 4.45 gm., 8
hourly, tab. Glimepiride 0.5mg with tab.
Metformin 500mg 12 hourly, tab. Thyroxin 62.5
mcg, tab telmisartan 40mg with tab.
Chlorthalidone 12.512.5 mg 12 hourly, Inj.-pan
40mg, 12 hourly, Inj.- Neomol 100ml, and Tablet-
nitrofurantoin 6 hourly.
3.3 Nursing Management
The nurse is in charge of prescribing the
medication and assessing its positive and
detrimental effects on the patients [7,8]. The
pharmacologic therapy type and dosage are
determined by the combination of these effects.
Actions to assess clinical effectiveness in nursing
include:
Observe for signs of difficulty with gait or
coordination and monitored for changes
in blood sugar levels with co-
administered drugs, monitored for pain level and
bleeding.
Perform an active, passive and isotonic range of
motion exercise as appropriate.
Check the bowel and bladder pattern of the
patient.
3.4 Nursing Diagnosis
1. Impaired thermoregulation related to
hyperthermia
2. Activity intolerance related to generalized
weakness
3. Burning micturition related to infection
secondary disease condition
4. The imbalanced nutritional pattern is less
than body requirement related to low
caloric intake and poor outcomes
associated with anorexia.
5. Deficient knowledge about self-care
activities related to reportable signs and
symptoms, treatment modalities and
medications.

Hatwar et al.; JPRI, 33(52A): 148-152, 2021; Article no.JPRI.75948
151
3.5 Collaborative Problems / Potential
Complications
1. Torsion
2. Intracyst huge
3. Infection
4. Rupture
5. Malignancy
6. Pseudomyxoma peritonei
3.6 Follow up
A referral to home care may be suggested for a
hospitalized patient depending upon the physical
condition of the patient and the availability of
family assistance. The patients with mucinous
Cystadenoma carcinoma had impaired physical
stamina often need home transfer assistance
after hospitalization. The home care nurse’s
assessment of the home’s physical environment
is important. Suggestions to adapt the home
environment to meet the limitation of the patient’s
activity are significant.
4. DISCUSSION
Mucinous Cystadenoma carcinoma is a type of
tumor in the cystadenocarcinoma grouping it can
occur in the breast as well as the ovary [9].
Tumors are normally multiocular with various
smooth thin-walled cysts. Within the cyst is found
an emergence or cellular debris [10].
4.1 Strength
The patient was 63 years female tolerate all the
medication and well response around 1 month to
the treatment of the hospital which was given as
a treatment.
5. CONCLUSION
Mucinous carcinoma is an invasive type of
cancer that begins in an internal organ that
produces much mucin, the primary ingredient of
mucus. The abnormal cells inside this type of
tumor are floating in the mucin, and the mucin
becomes a part of the tumor. Mucinous
Cystadenoma carcinoma is a benign cystic tumor
lined by a mucinous epithelium. It is a type of
cystic adenoma (cystadenoma).
INFORMED CONSENT
Before taking this case, information was given to
the patients and relatives and informed consent
was obtained from the patient as well as
relatives.
ETHICAL APPROVAL
We conducted our research after obtaining
proper IEC approval.
COMPETING INTERESTS
Authors have declared that no competing
interests exist.
REFERENCES
1. Uterine cervical elongation and prolapse
during pregnancy: an old unsolved
problem.
2. Stumbar SE, Stevens M, Feld Z,
Cervical Cancer and Its Precursors: A
Preventative Approach to Screening,
Diagnosis, and Management. Primary
Care; 2019.
3. Castle PE, Pierz A, (At Least) Once in Her
Lifetime: Global Cervical Cancer
Prevention. Obstetrics and gynecology
clinics of North America; 2019. [PubMed
PMID: 30683258]
4. Krishnan S, Madsen E, Porterfield D,
Varghese B. Advancing cervical cancer
prevention in India: Implementation
science priorities. Oncologist. 2013;
18:1285–97. [PMC free article] [PubMed]
[Google Scholar]
5. Ferlay J, Shin HR, Bray F, Forman D,
Mathers C, Parkin DM. Estimates of
worldwide burden of cancer in 2008:
GLOBOCAN 2008. Int J Cancer. 2010;
127:2893–917.
6. Jacob M. Information, education &
communication: Corner stone for
preventing cancer of the cervix. Indian J
Med Res. 2012;136:182–4. [PMC free
article]
7. Annamma Jacob. A Comprehensive
textbook of Midwifery & Gynecological
nursing, 4th edition, Published by Jaypee
brethren’s medical publishers, New Delhi.
2015;857-866.
8. Dutta DC. Textbook of gynaecology.
5th edition. Kolkata: New Central Book;
2008.
9. Yogev Y, Horowitz ER, Ben-Haroush A,
Kaplan B. Clin Exp Obstet Gynecol;
2003.

Hatwar et al.; JPRI, 33(52A): 148-152, 2021; Article no.JPRI.75948
152
[PMID: 14664405]
10. Aleven V, Stahl E, Schworm S, Fischer F,
Wallace R. Help seeking and help design
in interactive learning environments.
Review of Educational Research. 2003;73:
277-320.
© 2021 Hatwar et al.; This is an Open Access article distributed under the terms of the Creative Commons Attribution License
(http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium,
provided the original work is properly cited.
Peer-review history:
The peer review history for this paper can be accessed here:
https://www.sdiarticle5.com/review-history/75948